Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

The company's shares were trading at $739.23, on track for their worst single-day decline in nearly four years. Copenhagen-listed rival Novo Nordisk's shares also fell 3.5%. Lilly's stock went on ...

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...